8 июн 2017 г. - FDA requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market based on its concern that the benefits of the drug may no longer outweigh its risks.
Добавлено на ленту времени:
Дата:
8 июн 2017 г.
Сейчас
~ 8 гг и 4 мес назад